RQM+, a global MedTech regulatory and quality service provider, has launched a reimbursement division to provide its clients with reimbursement services, in addition to regulatory, quality, clinical and laboratory services, throughout the medical device and diagnostics product lifecycle. Daniel Lace, MD, will lead the new division and serve as chief medical officer (CMO) of RQM+.
Dr. Lace has more than 25 years of leadership experience as a healthcare executive across a wide range of managed care, pharmaceutical, device, diagnostic and consulting businesses. He has served as CMO and has held senior leadership positions in global pharmaceutical and medical device companies, as well as national managed care organizations.
“MedTech manufacturers are seeking reimbursement partners to manage increasingly complex challenges and ensure that reimbursement strategies are developed in tandem with regulatory strategies,” said Margaret Keegan, CEO of RQM+. “We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”
“It is a privilege to serve as CMO—providing strategic guidance for reimbursement as well as related services and technologies,” said Dr. Lace. “We look forward to helping customers navigate the complicated reimbursement and market access environment. We will use our extensive experience with the latest reimbursement requirements and value-based compensation models, as well as key payment trends, to provide customized support that fits each company’s needs.”